Cooper Companies (NASDAQ:COO) Director Buys $162,870.00 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Walter Rosebrough, Jr. acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average cost of $54.29 per share, with a total value of $162,870.00. Following the completion of the acquisition, the director owned 20,000 shares in the company, valued at $1,085,800. This trade represents a 17.65% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Cooper Companies Stock Performance

NASDAQ:COO traded down $0.95 during midday trading on Tuesday, reaching $53.27. The stock had a trading volume of 4,414,742 shares, compared to its average volume of 2,501,526. The stock has a market capitalization of $10.13 billion, a P/E ratio of 18.18, a PEG ratio of 2.19 and a beta of 0.82. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The firm’s fifty day simple moving average is $71.25 and its 200-day simple moving average is $69.40.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities research analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a stock buyback program on Wednesday, September 9th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Three directors purchased a combined 24,701 COO shares worth approximately $1.33 million at prices ranging from $53.18 to $54.29. The insider buying, including a 90% increase in Lawrence Kurzius’s holdings, may suggest that directors view the recent selloff as an attractive entry point. SEC insider purchase filing
• Neutral Sentiment: An investment analysis argued that Cooper Companies is becoming more compelling at its lower valuation. That view could support the stock if investors conclude that the weaker demand environment is temporary, although it does not change the company’s reduced guidance. Cooper Companies valuation analysis
• Negative Sentiment: Cooper cut fiscal 2026 adjusted EPS guidance to $4.51–$4.55 from $4.58–$4.66 and revenue guidance to $4.23–$4.25 billion from $4.29–$4.32 billion. The reductions reflect slowing contact-lens demand, particularly affecting the CooperVision business. Cooper Companies demand outlook
• Negative Sentiment: Reports said third-quarter results revealed U.S. channel inventory destocking and other negative surprises, intensifying concerns about near-term sales and distributor demand. A law firm has also announced an investigation into whether Cooper issued materially misleading business information, adding potential legal and reputational risk, though no wrongdoing has been established. Cooper Companies inventory report Rosen Law investigation announcement

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in COO. Sequoia Financial Advisors LLC grew its stake in shares of Cooper Companies by 290.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock valued at $2,459,000 after purchasing an additional 25,504 shares during the period. Tidal Investments LLC boosted its stake in Cooper Companies by 281.4% in the 2nd quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock valued at $5,945,000 after buying an additional 61,165 shares in the last quarter. National Pension Service grew its position in Cooper Companies by 9,314.0% in the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after acquiring an additional 520,560 shares during the period. WINTON GROUP Ltd grew its position in Cooper Companies by 379.0% in the second quarter. WINTON GROUP Ltd now owns 42,483 shares of the medical device company’s stock valued at $3,046,000 after acquiring an additional 33,613 shares during the period. Finally, Engineers Gate Manager LP raised its stake in Cooper Companies by 8,637.7% during the second quarter. Engineers Gate Manager LP now owns 249,897 shares of the medical device company’s stock worth $17,920,000 after acquiring an additional 247,037 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

COO has been the topic of several research analyst reports. Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies and gave the stock a “buy” rating in a research note on Thursday, September 10th. Robert W. Baird set a $61.00 target price on shares of Cooper Companies and gave the company a “neutral” rating in a research note on Thursday, September 10th. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. UBS Group decreased their price target on shares of Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Finally, Citigroup restated a “neutral” rating and set a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $71.47.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.